Chemistry 2011.org
Chemistry2011.org
All About Chemistry... 2011 and beyond

Related Stories

Promising New Biomarkers Linked to Early Diagnosis of Breast Cancer

Released: 1/6/2014 9:10 AM EST
Source Newsroom: American Association for Clinical Chemistry (AACC)
Contact Information

Available for logged-in reporters only

Citations Clinical Chemistry 60:1 233–242 (2014); Clinical Chemistry 60:1 197–205 (2014)

Jan. 7, 2014 - WASHINGTON – Two new papers in the “Advancing Women’s Health” issue of Clinical Chemistry, the journal of AACC, show for the first time that measuring the amount of certain protein fragments and microRNAs in a woman’s blood and breast tissue might enable the early diagnosis of breast cancer or prediction of its metastasis, respectively.

Share this story on Twitter.

Cancer is the second leading cause of death in both men and women in the U.S. However, women have a higher chance than men of being diagnosed with cancer before the age of 60 due to breast cancer development. Metastases in breast cancer’s later stages cause the majority of deaths associated with the disease, making early detection crucial to patient survival. Testing for the right biomarkers—biological molecules whose presence indicates a disease—could increase survival rates more than current screening methods such as mammography. Until recently, however, scientists have discovered disappointingly few useful cancer markers.

A team of researchers led by Ye Hu, PhD, of Weill Cornell Medical College of Cornell University, New York, has discovered several promising new biomarkers that could revolutionize the way breast cancer is diagnosed. In their paper, they show that levels of the enzyme carboxypeptidase N (CPN) are higher in breast cancer tissue than in healthy tissues. This enzyme produces six protein fragments, or peptides, that then enter the bloodstream. Hu’s team found that a rise in blood concentrations of these six peptides strongly correlates with increases of CPN, which in turn indicates the presence of breast cancer.

“Our results represent a first demonstration, to our knowledge, that clearly links the proteolytic activity of CPN, particularly at tumor sites, to the cleavage patterns of its catalytic substrates in the blood,” said Hu. “These biomarkers show strong potential for the noninvasive and early diagnosis of breast cancer. We advocate their use … certainly to be detected and identified before metastasis, and perhaps even before the tumor presents with any observable characteristics commonly used in the clinic.”

Another research team headed by Evi Lianidou, PhD, of the University of Athens, Athens, Greece, set out to address the current inability to predict at the time of breast cancer diagnosis whether a patient will experience a relapse or metastasis. Many recent studies have shown that microRNAs (miRNAs), a type of molecule that turns genes on and off, can play a critical role in the metastasis process. Upon examining this further, Lianidou’s team found that breast cancer patients who experienced quick relapses tended to have high and low levels of the microRNAs miR-21 and miR-205, respectively, in their tumor tissue. The team also discovered a connection between low levels of miR-205 and reduced overall survival.

Testing for these miRNAs or CPN-catalyzed peptides in early or potential breast cancer patients could ensure that women at risk of metastasis receive life-saving preventative treatment.

For more, follow us on Twitter at @_AACC and @Clin_Chem_AACC.
________________________________________
About AACC
Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry (AACC) brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Clinical Chemistry is the leading international journal of clinical laboratory science, providing 2,000 pages per year of peer-reviewed papers that advance the science of the field. With an impact factor of 7.9, Clinical Chemistry covers everything from molecular diagnostics to laboratory management.


Comment/Share


Share this story with your friends!

Social Networking

Please recommend us on Facebook, Twitter and more:

Other social media tools

Global Partners
Feedback

Tell us what you think of Chemistry 2011 -- we welcome both positive and negative comments. Have any problems using the site? Questions?

About us

Chemistry2011 is an informational resource for students, educators and the self-taught in the field of chemistry. We offer resources such as course materials, chemistry department listings, activities, events, projects and more along with current news releases.

Events & Activities

Are you interested in listing an event or sharing an activity or idea? Perhaps you are coordinating an event and are in need of additional resources? Within our site you will find a variety of activities and projects your peers have previously submitted or which have been freely shared through creative commons licenses. Here are some highlights: Featured Idea 1, Featured Idea 2.

About you

Ready to get involved? The first step is to sign up by following the link: Join Here. Also don’t forget to fill out your profile including any professional designations.

Global Partners